These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10372717)

  • 1. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.
    Thorner MO; Strasburger CJ; Wu Z; Straume M; Bidlingmaier M; Pezzoli SS; Zib K; Scarlett JC; Bennett WF
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2098-103. PubMed ID: 10372717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.
    Ross RJ; Leung KC; Maamra M; Bennett W; Doyle N; Waters MJ; Ho KK
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1716-23. PubMed ID: 11297608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human growth hormone antagonist B2036 does not interact with the prolactin receptor.
    Goffin V; Bernichtein S; Carrière O; Bennett WF; Kopchick JJ; Kelly PA
    Endocrinology; 1999 Aug; 140(8):3853-6. PubMed ID: 10433247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.
    Williams RM; Amin R; Shojaee-Moradie F; Umpleby AM; Acerini CL; Dunger DB
    Diabetologia; 2003 Sep; 46(9):1203-10. PubMed ID: 12898010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry.
    Tamshen K; Wang Y; Jamieson SMF; Perry JK; Maynard HD
    Bioconjug Chem; 2020 Sep; 31(9):2179-2190. PubMed ID: 32786367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-protein induced renal enlargement is growth hormone independent.
    van Neck JW; Cingel V; van Vliet AK; Drop SL; Flyvbjerg A
    Kidney Int; 2002 Oct; 62(4):1187-95. PubMed ID: 12234289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM; Hartman ML; Pezzoli SS; Harrell FE; Hintz RL; Alberti KG; Thorner MO
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Acting Human Growth Hormone Receptor Antagonists Produced in
    Wang Y; Langley RJ; Tamshen K; Jamieson SM; Lu M; Maynard HD; Perry JK
    Bioconjug Chem; 2020 Jun; 31(6):1651-1660. PubMed ID: 32423203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay.
    Veldhuis JD; Liem AY; South S; Weltman A; Weltman J; Clemmons DA; Abbott R; Mulligan T; Johnson ML; Pincus S
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3209-22. PubMed ID: 7593428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
    Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.
    Touraine P; D'Souza GA; Kourides I; Abs R; Barclay P; Xie R; Pico A; Torres-Vela E; Ekman B;
    Eur J Endocrinol; 2009 Oct; 161(4):533-40. PubMed ID: 19654233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.